Form 8-K - Current report:
SEC Accession No. 0001213900-24-056191
Filing Date
2024-06-26
Accepted
2024-06-26 16:40:52
Documents
14
Period of Report
2024-06-26
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0208572-8k_raphael.htm   iXBRL 8-K 25772
2 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF RAPHAEL PHARMACEUTICAL INC. DA ea020857201ex3-1_raphael.htm EX-3.1 22530
  Complete submission text file 0001213900-24-056191.txt   222907

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE raph-20240626.xsd EX-101.SCH 3054
4 XBRL LABEL FILE raph-20240626_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE raph-20240626_pre.xml EX-101.PRE 22385
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0208572-8k_raphael_htm.xml XML 3338
Mailing Address SUITE 105 - 5348 VEGAS DR. LAS VEGAS NV 89108
Business Address SUITE 105 - 5348 VEGAS DR. LAS VEGAS NV 89108 702-442-1166
Raphael Pharmaceutical Inc. (Filer) CIK: 0001415397 (see all company filings)

EIN.: 260204284 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-53002 | Film No.: 241074163
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)